About ELEGEN
Elegen is a biotechnology company founded in 2017 that develops a proprietary microfluidics-based, cell-free DNA synthesis platform (ENFINIA) to produce longer, higher-accuracy DNA at speed and scale. It serves agricultural, chemical, healthcare, and pharma industries with IVT-ready DNA, plasmid DNA, and clinical-grade DNA manufacturing solutions. The company's technology is designed to accelerate synthetic biology and genetic medicine workflows.
Company details
Funding
Total raised
$35M
Last stage
Growth
Investors
Founders
Matt Hill
PhD from Stanford with a proven track record of advancing innovative technologies from invention to commercial success. Founded Elegen in 2017 to eliminate the DNA bottleneck at the core of synthetic biology applications.
Marc Unger
Inventor of the Nanoflex™ valve and former CSO of Fluidigm. Leading biotechnology scientist advising and staffed at Elegen.
Dan La Caze
Matthew Hill
Dr. Matthew Hill holds a PhD from Stanford University and previously served as VP of Research & Development at Natera. He founded and leads Elegen with a track record of advancing innovative technologies from invention to commercial success.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.